216 related articles for article (PubMed ID: 30725231)
1. ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
Liu Y; Pandey PR; Sharma S; Xing F; Wu K; Chittiboyina A; Wu SY; Tyagi A; Watabe K
Breast Cancer Res Treat; 2019 May; 175(1):77-90. PubMed ID: 30725231
[TBL] [Abstract][Full Text] [Related]
2. LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
Deshpande RP; Sharma S; Liu Y; Pandey PR; Pei X; Wu K; Wu SY; Tyagi A; Zhao D; Mo YY; Watabe K
Breast Cancer Res; 2022 Jan; 24(1):6. PubMed ID: 35078502
[TBL] [Abstract][Full Text] [Related]
3. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
4. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
5. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
6. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
[TBL] [Abstract][Full Text] [Related]
7. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
10. Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms.
Brummer G; Acevedo DS; Hu Q; Portsche M; Fang WB; Yao M; Zinda B; Myers M; Alvarez N; Fields P; Hong Y; Behbod F; Cheng N
Mol Cancer Res; 2018 Feb; 16(2):296-308. PubMed ID: 29133591
[TBL] [Abstract][Full Text] [Related]
11. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
Hong Y; Limback D; Elsarraj HS; Harper H; Haines H; Hansford H; Ricci M; Kaufman C; Wedlock E; Xu M; Zhang J; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Aripoli A; Huppe A; Balanoff C; Wagner JL; Amin AL; Larson KE; Ricci L; Tawfik O; Razek H; Meierotto RO; Madan R; Godwin AK; Thompson J; Hilsenbeck SG; Futreal A; Thompson A; Hwang ES; Fan F; Behbod F;
J Pathol; 2022 Feb; 256(2):186-201. PubMed ID: 34714554
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
[TBL] [Abstract][Full Text] [Related]
13. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
[TBL] [Abstract][Full Text] [Related]
14. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
17. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
19. Everolimus Inhibits the Progression of Ductal Carcinoma
Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
[TBL] [Abstract][Full Text] [Related]
20. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]